Related Experiment Video
Updated: Nov 7, 2025
The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
Published on: November 19, 2008
Efferocytosis Mediated Modulation of Injury after Neonatal Brain Hypoxia-Ischemia
Jana Krystofova Mike1, Donna Marie Ferriero1,2
1Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA.
Insights
Neonatal brain hypoxia-ischemia (HI) poses significant risks. Stimulating efferocytosis, the clearance of dead cells, offers a promising therapeutic target for improving outcomes in infants affected by HI brain injury.
Area of Science:
- Neuroscience
- Immunology
- Neonatal Medicine
Background:
- Neonatal brain hypoxia-ischemia (HI) is a major cause of childhood neurological disability.
- Current therapies for HI are limited, necessitating novel treatment strategies.
- Efferocytosis, the process of clearing apoptotic cells, plays a crucial role in brain homeostasis.
Purpose of the Study:
- To review the role of efferocytosis in the context of neonatal brain hypoxia-ischemia (HI).
- To explore efferocytosis as a potential therapeutic target for HI brain injury.
Main Methods:
- Literature review focusing on efferocytosis mechanisms and their relevance to HI.
- Analysis of studies investigating efferocytosis in neurodevelopment and neurodegenerative diseases.
- Synthesis of evidence supporting efferocytosis modulation as a therapeutic strategy for HI.
Main Results:
- Efferocytosis is critical for clearing cellular debris after brain injury, including HI.
- Defective efferocytosis can exacerbate HI-induced damage.
- Stimulating efferocytosis has shown therapeutic potential in preclinical models of neurological conditions.
Conclusions:
- Efferocytosis represents a promising, yet under-explored, therapeutic target for neonatal HI.
- Further research into modulating efferocytosis could lead to novel treatments for HI brain injury.
- Targeting efferocytosis may offer a new avenue to mitigate long-term disabilities in affected children.
Abstract:
Neonatal brain hypoxia-ischemia (HI) is a leading cause of morbidity and long-term disabilities in children. While we have made significant progress in describing HI mechanisms, the limited therapies currently offered for HI treatment in the clinical setting stress the importance of discovering new targetable pathways. Efferocytosis is an immunoregulatory and homeostatic process of clearance of apoptotic cells (AC) and cellular debris, best described in the brain during neurodevelopment. The therapeutic potential of stimulating defective efferocytosis has been recognized in neurodegenerative diseases. In this review, we will explore the involvement of efferocytosis after a stroke and HI as a promising target for new HI therapies.
